Oruka Therapeutics (ORKA) news

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics has appointed L. Todd Edwards as its chief commercial officer (CCO), bringing extensive experience in the commercialization of dermatological and immunological therapies to the company. Edwards, who previously served as CCO at Arcutis Biotherapeutics, Inc., has over 25 years of…

Oruka Therapeutics - May offer up to $1 bln of securities - SEC filing

Oruka Therapeutics Inc. has filed with the U.S. Securities and Exchange Commission (SEC) to offer up to $1 billion in securities, according to a recent regulatory filing [1]. The offering, which has not yet commenced, is subject to market conditions and investor demand. The company did not specify…

Oruka Therapeutics Inc Q2 net income USD -41.206 million

Oruka Therapeutics Inc. reported a net loss of $24.574 million for the second quarter of 2025, representing slight increase in the deficit compared to $22.243 million in the same period in 2024. The company’s financial performance reflects ongoing investment in its clinical-stage pipeline,…

Oruka Therapeutics Inc: Leerink Partners raises target price to $162 from $120

Work Medical Technology Group - Bio Technologies to be primary U.S. operational platform for Work Medical

Work Medical Technology Group has positioned its Bio Technologies division as the primary operational platform for its U.S. activities, reflecting a strategic shift toward biotechnology-driven healthcare solutions. This move aligns with the growing demand for advanced medical biotechnology, as…